<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="781">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00168805</nctid>
  <trial_identification>
    <studytitle>RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery</studytitle>
    <scientifictitle>RE-MODEL (Thromboembolism Prevention After Knee Surgery). Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With a Half Dose (i.e.75 or 110 mg) on the Day of Surgery] Compared to Subcutaneous Enoxaparin 40 mg Once Daily for 6-10 Days</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2004-001317-34</secondaryid>
    <secondaryid>1160.25</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Arthroplasty, Replacement, Knee</healthcondition>
    <healthcondition>Thromboembolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - enoxaparin
Treatment: drugs - dabigatran etexilate
Treatment: drugs - dabigatran etexilate

Experimental: dabigatran etexilate 220 mg - 220 mg once daily

Experimental: dabigatran etexilate 150 mg - 150 mg once daily

Active Comparator: enoxaparin - 40 mg once daily


Treatment: drugs: enoxaparin
40 mg once daily

Treatment: drugs: dabigatran etexilate
150 mg once daily

Treatment: drugs: dabigatran etexilate
220 mg once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of Participants With Total Venous Thromboembolic Event and All-cause Mortality During Treatment Period - Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).
All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients.</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Major Venous Thromboembolic Event and Venous Thromboembolic Event-related Mortality During Treatment Period - Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Proximal Deep Vein Thrombosis During Treatment Period - Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Total Deep Vein Thrombosis During Treatment Period - Total Deep Vein Thrombosis as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Symptomatic Deep Vein Thrombosis During Treatment Period - Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Pulmonary Embolism During Treatment Period - Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants Who Died During Treatment Period - All cause death, as adjudicated by the VTE events committee</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Total Venous Thromboembolic Event (VTE) and All-cause Mortality During the Follow-up Period - Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Number of Participants With Bleeding Events (Defined According to Modified McMaster Criteria) During Treatment Period - Major bleeding events were defined as
fatal
clinically overt associated with loss of haemoglobin &gt;=20g/L in excess of what was expected
clinically overt leading to the transfusion of &gt;=2 units packed cells or whole blood in excess of what was expected
symptomatic retroperitoneal, intracranial, intraocular or intraspinal
requiring treatment cessation
leading to re-operation
Clinically-relevant was defined as
spontaneous skin hematoma greater than or equal to 25 cm²
wound hematoma greater than or equal to 100 cm²
spontaneous nose bleed lasting longer than 5 min
macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention
spontaneous rectal bleeding (more than a spot on toilet paper)
gingival bleeding lasting longer than 5 min
any other bleeding event considered clinically relevant by the investigator
Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above.</outcome>
      <timepoint>First administration until 6-10 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood Transfusion - Blood transfusion for treated and operated patients on Day of surgery.</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Volume of Blood Loss - Volume of blood loss for treated and operated patients during surgery.</outcome>
      <timepoint>Day 1</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Laboratory Analyses - Frequency of patients with possible clinically significant abnormalities.</outcome>
      <timepoint>First administration to end of study</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria

        Inclusion criteria (selected):

          -  Patients (18 years or older) scheduled to undergo a primary, unilateral, elect ive
             total knee replacement

          -  Written Informed Consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria

        Exclusion criteria (selected):

          -  Patients with an excessive risk of bleeding, for example because of history of
             bleeding diathesis major surgery or trauma within the last 3 months history of
             haemorrhagic stroke or any of the following intracranial pathologies: bleeding,
             neoplasm, arteriovenous (AV) malformation or aneurysm clinically relevant bleeding or
             gastric / duodenal ulcer within the last 6 months treatment with anticoagulants within
             7 days prior to joint replacement surgery or anticipated need during the study
             treatment period thrombocytopenia.

          -  Active malignant disease or current cytostatic treatment

          -  Known severe renal insufficiency

          -  Liver disease expected to have any potential impact on survival, or elevated aspartate
             aminotransferase (AST) or alanine transaminase (ALT) &gt; 2x upper limit of normal

          -  Recent unstable cardiovascular disease or history of myocardial infarction within the
             last 3 months

          -  Pre-menopausal women who are pregnant or nursing, or are of child-bearing pote ntial
             and are not practising or do not plan to continue practising acceptable me thods of
             birth control

          -  Allergy to radio opaque contrast media or iodine, heparins (incl. heparin indu ced
             thrombocytopenia) or dabigatran

          -  Contraindications to enoxaparin

          -  Participation in a clinical trial during the last 30 days</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>2101</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>ACT,NSW,SA,VIC,WA</recruitmentstate>
    <hospital>1160.25.06108 Boehringer Ingelheim Investigational Site - Garren</hospital>
    <hospital>1160.25.06106 Boehringer Ingelheim Investigational Site - Kogarah</hospital>
    <hospital>1160.25.06110 Boehringer Ingelheim Investigational Site - Lismore</hospital>
    <hospital>1160.25.06105 Boehringer Ingelheim Investigational Site - Bedford Park</hospital>
    <hospital>1160.25.06107 Boehringer Ingelheim Investigational Site - Toorak Gardens</hospital>
    <hospital>1160.25.06109 Boehringer Ingelheim Investigational Site - Woodville</hospital>
    <hospital>1160.25.06104 Boehringer Ingelheim Investigational Site - Box Hill</hospital>
    <hospital>1160.25.06102 Boehringer Ingelheim Investigational Site - Clayton</hospital>
    <hospital>1160.25.06101 Boehringer Ingelheim Investigational Site - Malvern</hospital>
    <hospital>1160.25.06103 Boehringer Ingelheim Investigational Site - Ringwood East</hospital>
    <hospital>1160.25.06113 Boehringer Ingelheim Investigational Site - Windsor</hospital>
    <hospital>1160.25.06111 Boehringer Ingelheim Investigational Site - Perth</hospital>
    <postcode> - Garren</postcode>
    <postcode> - Kogarah</postcode>
    <postcode> - Lismore</postcode>
    <postcode> - Bedford Park</postcode>
    <postcode> - Toorak Gardens</postcode>
    <postcode> - Woodville</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Clayton</postcode>
    <postcode> - Malvern</postcode>
    <postcode> - Ringwood East</postcode>
    <postcode> - Windsor</postcode>
    <postcode> - Perth</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Linz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wr. Neustadt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Genk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Gent</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Hasselt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Herentals</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Lanaken</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Brno-Bohunice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Chomutov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Havlickuv Brod</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kladno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Kolin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Ostrava</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Plzen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pradubice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Prague 8</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hellerup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Hørsholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>København NV</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>København S</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Silkeborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Helsinki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Jyväskylä</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Oulu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Seinäjoki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Annecy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Rochelle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris cedex 14</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Poitiers cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Roubaix cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Soyaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>St Etienne cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg cedex 2</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Mergentheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Erlangen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Frankfurt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Garmisch-Partenkirchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Halle/Saale</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Markgröningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinfelden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sommerfeld</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Wiesbaden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Békéscsaba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Gyula</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Kecskemét</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Székesfehérvár</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Parma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pavia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Piacenza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Reggio Emilia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Treviso</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Hilversum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Hoofddorp</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Nijmegen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Sittard</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zwolle</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kielce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Bryanston</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Randburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Sandton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alcorcón (Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Hospitalet (Barcelona)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Jaén</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Móstoles (Madrid)</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Falköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Göteborg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Halmstad</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Kungälv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Lidköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Linköping</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Mölndal</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Varberg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A phase III, randomised, parallel-group, double-blind, active controlled study to investigate
      the ef ficacy and safety of two different dose regimens of orally administered dabigatran
      etexilate capsule s [150 or 220 mg once daily starting with a half dose (i.e.75 or 110 mg) on
      the day of surgery] comp ared to subcutaneous enoxaparin 40 mg once daily for 6 to 10 days,
      in prevention of venous thromboem bolism in patients with primary elective total knee
      replacement surgery. RE-MODEL (Thromboembolism prevention after knee surgery)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00168805</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>